Evaluation and Management of Erythrocytosis with Elevated Rheumatoid Factor
The combination of erythrocytosis and elevated rheumatoid factor (RF) requires a systematic workup to distinguish between primary hematologic disorders (particularly polycythemia vera), secondary causes of erythrocytosis, and concurrent rheumatologic disease—with the critical first step being measurement of serum erythropoietin levels to guide the diagnostic pathway.
Initial Diagnostic Approach
Confirm True Erythrocytosis
First, verify that erythrocytosis is present by confirming hemoglobin >16.5 g/dL in men or >16 g/dL in women, with hematocrit >49% in men or >48% in women on repeat testing 1. This distinguishes absolute from relative erythrocytosis.
Measure Serum Erythropoietin Level
The erythropoietin (EPO) level is the critical branching point in your evaluation 2, 3:
- Low EPO: Indicates primary erythrocytosis (bone marrow disorder)
- Normal or elevated EPO: Indicates secondary erythrocytosis (external stimuli)
Evaluation Pathway Based on EPO Level
If EPO is Low (Primary Erythrocytosis)
Pursue hematologic workup for polycythemia vera (PV):
- JAK2 V617F mutation testing (most common)
- If JAK2 V617F negative, test for JAK2 exon 12 mutations
- Consider bone marrow biopsy if molecular testing is inconclusive 3
- Refer to hematology for specialized evaluation and management 2
The RF elevation in this scenario is likely coincidental or related to a separate autoimmune process, as RF positivity occurs in various conditions beyond rheumatoid arthritis 4.
If EPO is Normal or Elevated (Secondary Erythrocytosis)
Investigate secondary causes systematically 1, 2:
Cardiopulmonary evaluation:
- Pulse oximetry and arterial blood gas (chronic hypoxemia)
- Chest imaging and pulmonary function tests
- Echocardiography for right-to-left shunts
- Sleep study if obstructive sleep apnea suspected
Other secondary causes:
- Smoking history (carboxyhemoglobinemia)
- Medication review (androgens, erythropoietin-stimulating agents)
- Renal imaging (renal cell carcinoma, renal artery stenosis, polycystic kidney disease)
- Liver function tests (hepatocellular carcinoma)
Congenital causes (especially if young patient or positive family history) 5:
- High-affinity hemoglobin variants
- Mutations in oxygen-sensing pathway genes (VHL, EPAS1, EGLN1)
Addressing the Elevated Rheumatoid Factor
Determine Clinical Significance
RF positivity alone does not equal rheumatoid arthritis 4. The study of 230 RF-positive patients found:
- Only 62.2% had rheumatoid arthritis as the final diagnosis
- RF levels 20-50 IU/mL had significantly lower rates of rheumatic disease
- RF can be positive in elderly patients, infections, other autoimmune diseases, and lymphoproliferative disorders
Assess for Rheumatoid Arthritis
Look for specific clinical features:
- Symmetric polyarthritis, particularly involving small joints of hands and feet
- Morning stiffness >30 minutes
- Joint swelling and tenderness
- Radiographic erosions
Additional serologic testing:
- Anti-CCP antibodies (more specific for RA than RF alone) 4
- ANA testing
- Inflammatory markers (ESR, CRP)
Important caveat: Anemia is the typical hematologic finding in RA patients, not erythrocytosis 6. The presence of erythrocytosis makes RA less likely to be the primary driver of the clinical picture.
Management Considerations
For Confirmed Polycythemia Vera
- Low-dose aspirin (81 mg daily)
- Phlebotomy to maintain hematocrit <45% in men, <42% in women 7
- Cytoreductive therapy if high-risk features present
For Secondary Erythrocytosis
Direct treatment at the underlying cause 1:
- Optimize cardiopulmonary disease
- Smoking cessation
- Discontinue causative medications
- Surgical intervention for tumors if indicated
- Consider phlebotomy only if symptomatic hyperviscosity
If Rheumatoid Arthritis is Confirmed
Follow ACR 2021 guidelines for RA treatment 8, but note an important therapeutic consideration: High serum RF levels are associated with reduced response to TNF inhibitors with Fc regions 9, 10. If RF levels are markedly elevated (>500 IU/mL) and TNF inhibitor therapy is needed, certolizumab pegol (which lacks an Fc region) may maintain better efficacy as it is less likely to bind RF and undergo degradation.
Clinical Pitfalls to Avoid
Do not assume RF positivity equals RA diagnosis—RF has poor specificity, particularly at lower titers 4
Do not overlook congenital causes in young patients or those with family history of erythrocytosis 5
Do not delay hematology referral if EPO is low or if no secondary cause is identified after initial workup 2
Remember that RA typically causes anemia, not erythrocytosis—the coexistence suggests two separate processes 6
Measure EPO before initiating phlebotomy, as this can alter the diagnostic workup 3